Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Disc Medicine (IRON)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Edwards Lifesciences (EW)
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Edwards Lifesciences today and set a price target of $110.00. The company’s shares closed last Wednesday at $77.62.
According to TipRanks.com, Wise is a 1-star analyst with an average return of
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $97.33, a 26.7% upside from current levels. In a report issued on January 30, Piper Sandler also maintained a Buy rating on the stock with a $98.00 price target.
See today’s best-performing stocks on TipRanks >>
Disc Medicine (IRON)
Wedbush analyst David Nierengarten maintained a Buy rating on Disc Medicine today and set a price target of $110.00. The company’s shares closed last Wednesday at $75.63.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $123.44, implying a 67.9% upside from current levels. In a report issued on January 28, BMO Capital also maintained a Buy rating on the stock with a $120.00 price target.
